SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) —

Capricor Therapeutics

(NASDAQ: CAPR) (“Capricor” or “the Company”), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that Dr. Linda Marbán, CEO of Capricor, has accepted an invitation to serve as the keynote speaker at the

TriLink Biotechnologies

Annual mRNA Day Conference, taking place virtually on November 16, 2021.

The global event, in partnership with Genetic Engineering News (GEN) and The CRISPR Journal, will provide a broad platform to discuss mRNA-based vaccines and therapeutics across various disease areas. As a distinguished opinion leader, Dr. Marbán will discuss the development of mRNA therapeutics and the emergence of new delivery platforms, including exosomes.

“Given the emergence of mRNA technology in the fight against COVID-19, now, more than ever, there is a need for both the medical community and the general public to better understand the promise mRNA holds in combatting diseases,” said Dr. Linda Marbán, CEO, Capricor Therapeutics. “As we embark on this new era of vaccinology, Capricor looks forward to working alongside other biopharma trailblazers such as TriLink to turn the tide in how we approach drug development.”

In November of 2019, the City and County of San Diego officially proclaimed “mRNA Day” to honor the grand opening of the TriLink BioTechnologies facility and Maravai LifeSciences headquarters. Through this event, industry leaders will gather to share their scientific knowledge, research expertise, and predictions for the future. You can register for TriLink’s Annual mRNA Day here:

https://live.classy.org/register/annual-mrna-day/8a0fbc4a-8a2e-43ed-aa45-a491388a3b10

.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on developing transformative cell- and exosome-based therapeutics and vaccines for treating and preventing a broad spectrum of diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology as a next-generation therapeutic platform. The Company’s current focus is on developing exosomes loaded with nucleic acids, including mRNA, to treat or prevent a variety of diseases. For more information, visit

www.capricor.com

, and follow the Company on

Facebook

,

Instagram

and

Twitter

.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on March 15, 2021, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 as filed with the Securities and Exchange Commission on November 12, 2021. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.

For more information, please contact:

Media Contact

:

Raquel Cona

KCSA Strategic Communications


[email protected]


212.896.1204

Investor Contact

:

Joyce Allaire

LifeSci Advisors, LLC


[email protected]


617.435.6602

Company Contact

:

AJ Bergmann, Chief Financial Officer


[email protected]




310.358.3200